Publications by authors named "Hitomi Morishima"

Claim this Profile
S
Sustained efficacy and safety of guselkumab in patients with palmoplantar pustulosis through 1.5 years in a randomized phase 3 study.
Yukari Okubo, Hitomi Morishima, Richuan Zheng, Tadashi Terui

J Dermatol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Guselkumab in Japanese Patients With Palmoplantar Pustulosis: A Phase 3 Randomized Clinical Trial.
Tadashi Terui, Satomi Kobayashi, Yukari Okubo, Masamoto Murakami, Richuan Zheng, Hitomi Morishima

JAMA Dermatol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study.
Mamitaro Ohtsuki, Hiroshi Kubo, Hitomi Morishima, Ryosuke Goto, Richuan Zheng

J Dermatol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study.
Shigetoshi Sano, Hiroshi Kubo, Hitomi Morishima, Ryosuke Goto, Richuan Zheng

J Dermatol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transmitochondrial mito-miceΔ and mtDNA mutator mice, but not aged mice, share the same spectrum of musculoskeletal disorders.
Takayuki Mito, Hikari Ishizaki, Michiko Suzuki, Hitomi Morishima, Azusa Ota

Biochem Biophys Res Commun· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis